Article Text

Download PDFPDF
Agreement Between Magnetic Resonance Imaging and Pathologic Findings in the Tumor Size Evaluation Before and After Neoadjuvant Chemotherapy Treatment: A Prospective Study
  1. Jinlong Cheng, MS*,
  2. Yan Hou, PhD,,
  3. Junnan Li, PhD,
  4. Wenjie Wang, MS,
  5. Ye Xu, MD*,
  6. Chunyan Yang, MS,
  7. Libing Ma, MS,
  8. Harman S. Dhillon, PhD§,
  9. Margarita S. Openkova, PhD§,
  10. Xin Fan, PhD,
  11. Zhenzi Li, PhD,
  12. Kang Li, PhD and
  13. Ge Lou, MD*
  1. * Department of Gynecology Oncology, The Affiliated Tumor Hospital of Harbin Medical University;
  2. Department of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University;
  3. Key Laboratory of Cardiovascular Medicine Research (Harbin Medical University), Ministry of Education;
  4. § Harbin Medical University; and
  5. Basic Medicine School, Heilongjiang University of Chinese Medicine, Harbin, People’s Republic of China.
  1. Address correspondence and reprint requests to Ge Lou, MD, Department of Gynecology Oncology, The Tumor Hospital, Harbin Medical University, Harbin 150086, People’s Republic of China. E-mail: louge{at}ems.hrbmu.edu.cn; or Kang Li, PhD, Department of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University, Harbin 150086, People’s Republic of China. E-mail: likang{at}ems.hrbmu.edu.cn.

Abstract

Objectives To compare the agreement between magnetic resonance imaging (MRI) results and postsurgical pathologic findings for tumor size evaluation in cervical cancer patients before and after neoadjuvant chemotherapy (NACT) treatment.

Methods The study analyzed the agreement between pretreatment MRI results and postsurgical pathologic findings about the tumor size in 100 cervical cancer patients without NACT and 397 cervical cancer patients with NACT, respectively.

Results In general, the agreement between pretreatment MRI results and postsurgical pathologic findings of tumor size was 0.855 (95% confidence interval [CI], 0.763–0.909) in cervical cancer patients without NACT, whereas the agreement between posttreatment MRI results and postsurgical pathologic findings was 0.503 (95% CI, 0.421–0.576). Only 62.72% (249/397) of patients who underwent NACT treatment have the same chemotherapy response evaluation results; the κ coefficient was 0.384(95% CI, 0.310–0.457) between posttreatment MRI and postsurgical pathologic findings. We still found International Federation of Gynecology and Obstetrics stage is associated with the chemotherapy response evaluation.

Conclusions Our data suggest that pretreatment MRI can be a surrogate indicator for postsurgical pathologic findings. However, posttreatment MRI could not be a surrogate indicator for postsurgical pathologic findings. The chemotherapy response evaluation based on only MRI is not so reliable. More indicators should be developed for chemotherapy response evaluation.

  • Agreement
  • MRI
  • Neoadjuvant chemotherapy
  • Response

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.